Cleveland Clinic has joined forces with DASI Simulations to co-develop next-generation AI predictive modeling solutions for structural heart diseases. This landmark collaboration also deploys DASI’s existing technology to support planning and treatment for current TAVR patients at Cleveland Clinic. Together, these two organizations are pushing the boundaries of what modern cardiac care can achieve.
A Groundbreaking Partnership in Cardiology
Two industry leaders are combining their strengths in this ambitious two-year co-development project. Cleveland Clinic brings deep clinical expertise and extensive patient data to the table. DASI, in turn, contributes advanced AI models and physics-based simulation technology. Together, they aim to raise the standard of care for structural heart disease patients across the country.
“We’re committed to innovating in the cardiovascular field for both patients and providers,” said Samir Kapadia, M.D., Chairman of Cardiovascular Medicine at Cleveland Clinic. “Developing AI models to guide TAVR during the procedure will further enhance safety and ensure optimal valve selection.”
Cleveland Clinic is also an investor in DASI Simulations. Consequently, the institution may benefit financially from the future commercial success of this technology — a clear signal of its long-term commitment to this innovation.
What Is TAVR and Why It Matters
Understanding the Procedure
Transcatheter Aortic Valve Replacement, or TAVR, is a minimally invasive procedure. It replaces a diseased aortic valve with an artificial one. Importantly, it requires no open-heart surgery. As a result, patients experience shorter recovery times and fewer surgical risks. TAVR has transformed the treatment of aortic valve disease, particularly for high-risk surgical patients.
The Current Challenge in TAVR Planning
Despite TAVR’s advantages, precise procedure planning remains critical. Physicians must select the correct valve size and anticipate potential complications before the procedure begins. Currently, this process relies heavily on manual analysis of imaging data. That approach introduces variability and leaves room for error. A smarter, AI-driven system can close this gap in a meaningful way.
Building the World’s First AI Co-Pilot for Cardiac Labs
The core goal of this partnership is groundbreaking: to create the world’s first AI-powered “co-pilot” system for catheterization labs. This real-time support system will assist doctors during live heart procedures. It combines Cleveland Clinic’s clinical datasets with DASI’s advanced AI models to provide patient-specific guidance on valve selection and procedural decisions.
“Partnering with Cleveland Clinic allows us to bring AI-driven, physics-based simulation directly into clinical practice,” said DASI Founder and CEO Teri Sirset. “Together, we are pioneering a new era of personalized medicine, transforming how structural heart procedures are planned and executed.”
Furthermore, DASI’s Chief Technology Officer Lakshmi Dasi, Ph.D., FACC, FAIMBE, shared a broader vision for the technology. “With our next-generation products, I see us truly democratizing decision-making in structural heart procedures,” he said. “This will enable the highest quality care, improve outcomes, and ultimately reduce healthcare costs.”
DASI’s FDA-Cleared Technology in Action
PrecisionTAVI™ — A First-of-Its-Kind Platform
DASI’s flagship product, PrecisionTAVI™, stands out as the only FDA-cleared product with a CMS reimbursement code in the structural heart therapy domain. The platform converts routine CT scan imaging into a four-dimensional predictive environment. Physicians then use this environment to personalize their treatment approach based on each patient’s unique anatomy. Studies have consistently shown measurable improvements in patient outcomes with this technology.
DASI Dimensions™ and the Road Ahead
DASI currently markets two FDA-cleared products: PrecisionTAVI™ and DASI Dimensions™. Both tools harness artificial intelligence and computer vision to support surgical planning. Moreover, they enable surgeons to identify and prepare for potential complications before entering the operating room. This proactive approach reduces procedural costs and improves outcomes for structural heart disease patients at scale.
What This Means for Patients
Patients stand to benefit most from this collaboration. Today, TAVR planning depends heavily on physician experience and manual imaging review. Tomorrow, AI will guide those decisions in real time. Doctors will receive intelligent, patient-specific recommendations at every stage of the procedure. Additionally, this technology has the potential to extend high-quality decision support beyond major academic medical centers to hospitals across the country.
This is not just a technological upgrade. It is a fundamental shift in how doctors and machines work together inside the cardiac care environment.
About the Organizations
Cleveland Clinic
Cleveland Clinic is a nonprofit multispecialty academic medical center founded in 1921. It employs more than 5,786 salaried physicians and researchers across 140 medical specialties. The institution has pioneered numerous medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. It consistently ranks among the world’s top hospitals.
DASI Simulations
Founded in 2020 and based in Dublin, Ohio, DASI Simulations specializes in advanced individualized computational predictive modeling for heart surgery candidates. Its AI- and computer-vision-powered tools help surgeons plan procedures with greater precision and confidence. For more information, visit dasisim.com.
